FDA Accepts Supplement for Trodelvy (Sacituzumab Govitecan-Hziy)
The FDA has accepted a supplemental application for Trodelvy, indicating ongoing development and potential label expansion.
Therapeutic Area
Therapeutic area intelligence for Antibody-Drug Conjugate with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.